Octreoanne (Octreotide Acetate)

Octreotide acetate, the active ingredient in Octreoanne, is a somatostatin analog presented as a formulation for injection use. It regulates hormone‑secreting tumors and related endocrine disorders in adults. GNH USA supplies Octreoanne as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

GNH USA supplies Octreoanne as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Octreoanne is a somatostatin analog that modulates hormone‑secretion pathways in several endocrine disorders.

- Acromegaly: reduces excessive growth‑hormone production and helps control disease activity. - Neuroendocrine tumors: controls hormone‑related symptoms such as flushing and diarrhea. - Carcinoid syndrome: diminishes flushing, bronchospasm and diarrhoea associated with serotonin excess. - VIPoma syndrome: lowers severe watery diarrhoea caused by vaso‑active intestinal peptide. - Post‑operative ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ ​

Octreoanne may cause a range of adverse reactions, most of which are mild to moderate in intensity.

Common Side Effects: - Nausea and vomiting - Abdominal pain or cramping - Diarrhoea - Injection site reactions such as erythema or swelling - Headache - Flushing

Serious or Rare Side Effects: - Gallbladder sludge or gallstones - Hyperglycaemia or hypoglycaemia - Severe allergic reactions (anaphylaxis) - Cardiac arrhythmia   t  

Octreoanne            …   g        …   ewline       ewline    ".  d